The Swiss drugmaker Novartis has taken the opportunity to boost its haematology pipeline by exercising an option to acquire the US-based sickle cell disease specialist Selexys Pharmaceuticals. The move, which…
Novartis strengthens haematology presence
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at email@example.com and we will call you to discuss.
Already a subscriber? Login here